Table 2.
Potential of propolis in maintaining metabolizing enzymes. (Values are mean ± SE from six rats in each group.)
| Groups | Adenosine triphosphatase | Acid phosphatase | Alkaline phosphatase | |||
|---|---|---|---|---|---|---|
| (mg Pi/100 mg/min) | (mg Pi/100 mg/h) | (mg Pi/100 mg/h) | ||||
| Hepatic | Renal | Hepatic | Renal | Hepatic | Renal | |
| Control | 2020 ± 111 | 2500 ± 138 | 250 ± 30.9 | 270 ± 14.9 | 74.0 ± 4.09 | 2580 ± 142 |
| CCl4 | 987 ± 54.5# | 1095 ± 60.5# | 1395 ± 77.1# | 1440 ± 79.6# | 36.0 ± 1.99# | 716 ± 39.6# |
| CCl4 + Propolis | 1742 ± 96.2* | 1775 ± 98.1* | 338 ± 18.7* | 378 ± 20.9* | 68.0 ± 3.75* | 1591 ± 87.9* |
| % Protection | 73.1% | 48.4% | 92.3% | 90.7% | 84.2% | 46.9% |
| CCl4 + Silymarin | 1806 ± 99.8* | 1880 ± 232* | 335 ± 18.5* | 342 ± 18.9* | 69.0 ± 3.81* | 1665 ± 92.1* |
| % Protection | 79.3% | 55.8% | 92.6% | 93.8% | 86.8% | 50.9% |
|
| ||||||
| F Variance | 28.1† | 36.7† | 208† | 202† | 29.3† | 73.1† |
P value CCl4 versus control at #≤0.05; therapy versus CCl4 at ∗ ≤ 0.05; †significant for analysis of variance P ≤ 0.05.